Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study[J]. JAMA, 2006, 295(21): 2492-2502.
[2]
Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumors[J]. Nature, 2000, 406(6797): 747-752.
[3]
Ihemelandu CU, Naab JT, Mezghebe HM, et al. Basal cell-like (triple-negative) breast cancer, a predictor of distant metastasis in African American women[J]. Am J Surg, 2008, 195(2): 153-158.
[4]
Ihemelandu CU, Naab JT, Mezghebe HM, et al. Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival[J]. J Surg Res, 2007, 143(1): 109-118.〖ZK)〗
[5]
Srlie T. Molecular portraits of breast cancer: tumour subtypes as distinct disease entities[J]. Eur J Cancer, 2004, 40(18): 2667-2675.
[6]
Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma[J]. Mod Pathol, 2006, 19(2): 264-271.
[7]
Kim MJ, Ro JY, Ahn SH, et al. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes[J]. Hum Pathol, 2006, 37(9): 1217-1226.
Voduc KD, Cheang MC, Tyldesley S, et al. Breast cancer subtypes and the risk of local and regional relapse[J]. J Clin Oncol, 2010, 28(10): 1684-1691.
[10]
Wong FY, Chin FK, Lee KA, et al. Hormone receptors and her-2 status as surrogates for breast cancer molecular subtypes prognosticate for disease control in node negative asian patients treated with breast conservation therapy[J]. Ann Acad Med Singapore, 2011, 40(2): 90-97.
[11]
Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes[J]. Clin Cancer Res, 2007, 13(8): 2329-2334.
[12]
Liu H, Fan Q, Zhang Z, et al. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers[J]. Hum Pathol, 2008, 39(2): 167-174.
[13]
Badve S, Turbin D, Thorat MA, et al. FOXA1 expression in breast cancer-correlation with luminal subtype A and survival[J]. Clin Cancer Res, 2007, 13(15 Pt 1): 4415-4421.
[14]
Millikan RC, Newman B, Tse CK, et al. Epidemiology of basal-like breast cancer[J]. Breast Cancer Res Treat, 2008, 109(1): 123-139.
[15]
Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy[J]. Clin Cancer Res, 2005, 11(16): 5678-5685.
